Company Overview
| Stock Name | Ascentage |
|---|---|
| Stock Code | 06855 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一間放眼全球的臨床階段生物科技公司,從事開發治療癌症、乙型肝炎病毒(HBV)及衰老相關疾病的新型療法。已研發出包括八項處於臨床階段的小分子候選藥物在內的豐富在研產品,涵蓋蛋白-蛋白相互作用(PPI)及下一代酪氨酸激酶抑制劑(TKI)。 |
| Listing Date | 2019-10-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 江蘇省蘇州市蘇州工業園區星湖街218號B7樓7層 |
| Business Address (Hong Kong) | 香港中環皇后大道中149號華源大廈9樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | ascentagepharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 34.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-10-16 to 2019-10-21 |
| Global Offering Shares | 12,180,900 shares |
| HK Public Offer Shares (Initial) | 1,218,200 shares (10.0%) |
| Public Offer Lots (Initial) | 12,182lots (Pool A6,091lots,Pool B6,091lots) |
| International Placing Shares (Initial) | 10,962,700 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 207,074,627 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 37.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 416,586,780 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 3,420 |
| 2 lots | 200 | HK$ 6,840 |
| 3 lots | 300 | HK$ 10,260 |
| 4 lots | 400 | HK$ 13,680 |
| 5 lots | 500 | HK$ 17,100 |
| 6 lots | 600 | HK$ 20,520 |
| 7 lots | 700 | HK$ 23,940 |
| 8 lots | 800 | HK$ 27,360 |
| 9 lots | 900 | HK$ 30,780 |
| 10 lots | 1,000 | HK$ 34,200 |
| 20 lots | 2,000 | HK$ 68,400 |
| 30 lots | 3,000 | HK$ 102,600 |
| 40 lots | 4,000 | HK$ 136,800 |
| 50 lots | 5,000 | HK$ 171,000 |
| 60 lots | 6,000 | HK$ 205,200 |
| 70 lots | 7,000 | HK$ 239,400 |
| 80 lots | 8,000 | HK$ 273,600 |
| 90 lots | 9,000 | HK$ 307,800 |
| 100 lots | 10,000 | HK$ 342,000 |
| 200 lots | 20,000 | HK$ 684,000 |
| 300 lots | 30,000 | HK$ 1,026,000 |
| 400 lots | 40,000 | HK$ 1,368,000 |
| 500 lots | 50,000 | HK$ 1,710,000 |
| 600 lots | 60,000 | HK$ 2,052,000 |
| 700 lots | 70,000 | HK$ 2,394,000 |
| 800 lots | 80,000 | HK$ 2,736,000 |
| 900 lots | 90,000 | HK$ 3,078,000 |
| 1,000 lots | 100,000 | HK$ 3,420,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 200,000 | HK$ 6,840,000 |
| 3,000 lots | 300,000 | HK$ 10,260,000 |
| 4,000 lots | 400,000 | HK$ 13,680,000 |
| 5,000 lots | 500,000 | HK$ 17,100,000 |
| 6,000 lots | 600,000 | HK$ 20,520,000 |
| 6,091 lots | 609,100 | HK$ 20,831,220 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 13.87B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣345.3百萬元 |
| Period-End Cash Balance | 人民幣957.1百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 人民幣14億元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016-12 |
|---|---|
| Other income and gains, net | 218 |
| Administrative expenses | -1,292 |
| Profit before tax | -8,464 |
| Income tax expense | 0 |
| Profit for the year | -8,464 |
Balance Sheet
| Item | 2016-12 | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 6,097 | ||||
| Total current assets | 6,841 | ||||
| Total current liabilities | 10,439 | ||||
| Total equity | -9,629 | ||||
| Interest-bearing borrowings | 830 | 4,898 | 42,044 | 120,114 |
Cash Flow Statement
| Item | 2016-12 | 2016 | 2017 | 2018 | 2019-06 |
|---|---|---|---|---|---|
| Net cash from operating activities | 1,250 | ||||
| Net cash from investing activities | -225 | ||||
| Net increase in cash | 1,025 | ||||
| Depreciation of PP&E | 1,085 | 3,924 | 7,640 | 4,760 | |
| Depreciation of right-of-use assets | 455 | 2,157 | 4,098 | 4,197 | |
| Amortisation of intangible assets | 7 | 6,420 | 6,724 | 3,479 | |
| Purchase of PP&E | -3,285 | -20,536 | -14,257 | -17,050 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 37.6 |
|---|---|
| First Day Open | HK$ 53.0 |
| First Day Change | 9.94% |
| First Day Volume | 13246000.0 |
| First Day Turnover | 594180000.0 |
| Use of Proceeds | 1、所得款項凈額約42%(約130.9百萬港元)分配到研發,將核心產品HQP1351商業化
2、所得款項凈額約13%(約40.5百萬港元)用于APG-1252持續及規劃臨床試驗;
3、所得款項凈額約19%(約59.2百萬港元)用于APG-2575持續及規劃臨床試驗;
4、所得款項凈額約19%(約59.2百萬港元)用于APG-115持續及規劃臨床試驗;
5、所得款項凈額約6%(約18.7百萬港元)分配到APG-1387及APG-2449其余臨床計劃的持續及規劃臨床試驗;
6、所得款項凈額約1%(約3.1百萬港元)分配到我們的營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198
Citigroup Global Markets Asia Limited CE AAA137
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
建银国际金融有限公司 CE AJO225
China Renaissance Securities (Hong Kong) Limited CE AZX839
CMB International Capital Holdings Corporation Limited CE AJB801
海通国际证券有限公司 CE AAF806
Joint Lead Managers (7)
Merrill Lynch (Asia Pacific) Limited CE AAC198
Citigroup Global Markets Asia Limited CE AAA137
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
建银国际金融有限公司 CE AJO225
China Renaissance Securities (Hong Kong) Limited CE AZX839
CMB International Capital Holdings Corporation Limited CE AJB801
海通国际证券有限公司 CE AAF806
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 中国生物制药有限公司 | 156,854,880 HKD | — | 37.65% | — | 6 months | 2020-04-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 楊大俊 | — |
| Company Secretary | 王章旗 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 楊博士、王博士、郭博士、翟博士及創辦人特殊目的公司、翟博士特殊目的公司為一致行動人,合共持有約32.45%股權;田源博士透過受控法團持有約9.87%及實益持有0.14%;先進製造產業投資有限公司持有約9.21%。 |
|---|




